Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’
Titel:
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’
Auteur:
Schöffski, Patrick Mir, Olivier Kasper, Bernd Papai, Zsuzsanna Blay, Jean-Yves Italiano, Antoine Benson, Charlotte Kopeckova, Katerina Ali, Nasim Dileo, Palma LeCesne, Axel Menge, Franka Cousin, Sophie Wardelmann, Eva Wozniak, Agnieszka Marreaud, Sandrine Litiere, Saskia Zaffaroni, Facundo Nzokirantevye, Axelle Vanden Bempt, Isabelle Gelderblom, Hans